ERBB2 and breast carcinoma: Recent in-vitro studies showed that delphinidin can inhibit the invasion of HER-2-positive MDA-MB-453 breast cancer cell line, with low cytotoxicity on normal breast cells (Wu et al., 2021) and ovarian cancer cells (Lim et al., 2017) and can also induce autophagy in breast cancer cells (Chen et al., 2018).